Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T W Kim

Showing results (221-230 of 240) with videos related to

Pageof 24
Sort By:
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 14, 2022
Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O<sup>6</sup>-Methylguanine DNA Methyltransferase Status: KCSG-CO17-02C R Oh, J E Kim, J S Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2026
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3S Kopetz, J Tabernero, S Lonardi, et al.
Archives of Surgery (Chicago, Ill. : 1960)|August 17, 2005
Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitusGarth L Warnock, R Mark Meloche, David Thompson, et al.
British Journal of Cancer|October 28, 2015
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancerS H Lim, T W Kim, Y S Hong, et al.
British Journal of Cancer|March 2, 2013
Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201)Y-K Kang, H-M Chang, J H Yook, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2024
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 studyT André, K-K Shiu, T W Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2018
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III studyT Yoshino, D C Portnoy, R Obermannová, et al.
Oncogene|May 31, 2016
Foxp3 is a key downstream regulator of p53-mediated cellular senescenceJ-E Kim, J-S Shin, J-H Moon, et al.
Oncogenesis|January 17, 2017
API5 confers cancer stem cell-like properties through the FGF2-NANOG axisK-H Song, H Cho, S Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 29, 2019
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumorsM D Hellmann, T-W Kim, C B Lee, et al.
Pageof 24

Showing results (221-230 of 240) with videos related to

Sort By:
Pageof 24
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 14, 2022
Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O<sup>6</sup>-Methylguanine DNA Methyltransferase Status: KCSG-CO17-02C R Oh, J E Kim, J S Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2026
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3S Kopetz, J Tabernero, S Lonardi, et al.
Archives of Surgery (Chicago, Ill. : 1960)|August 17, 2005
Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitusGarth L Warnock, R Mark Meloche, David Thompson, et al.
British Journal of Cancer|October 28, 2015
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancerS H Lim, T W Kim, Y S Hong, et al.
British Journal of Cancer|March 2, 2013
Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201)Y-K Kang, H-M Chang, J H Yook, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2024
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 studyT André, K-K Shiu, T W Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2018
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III studyT Yoshino, D C Portnoy, R Obermannová, et al.
Oncogene|May 31, 2016
Foxp3 is a key downstream regulator of p53-mediated cellular senescenceJ-E Kim, J-S Shin, J-H Moon, et al.
Oncogenesis|January 17, 2017
API5 confers cancer stem cell-like properties through the FGF2-NANOG axisK-H Song, H Cho, S Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 29, 2019
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumorsM D Hellmann, T-W Kim, C B Lee, et al.
Pageof 24